drugset / Trial / NCT05794581

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581

Phase 1 Completed 32 enrolled Carmot Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Timeline

Start
2023-03-21
Primary completion
2024-03-06
Completion
2024-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CT-868 Unknown Subcutaneous
Comparator Liraglutide Peptide Subcutaneous